🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

AR

Artelo Biosciences IncNASDAQ ARTL Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ARTL undervalued compared to its fair value?

The fair value of ARTL stock is hidden USD. Relative to the market price of 1.295 USD Artelo Biosciences Inc is hidden.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquar...[More about valuation]

Artelo Biosciences Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.004 $B

Price:

1.295 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.831

FINANCIALS

Artelo Biosciences financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0026 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0025 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.015 B
0.015 B

Financial Position Analysis

Assets

0.015 B
Current Assets
0.013 B
Total non-current assets
0.0021 B

Total current liabilities
0.0009 B
Total non-current liabilities

Cash Flow Statement

-0.0018 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0018 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Artelo Biosciences fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ARTL attractive for investment based on fundamental analysis?

ARTL stock rating is hidden. Artelo Biosciences is a hidden by Eyestock methodology.

Get ARTL Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ARTL analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ARTL to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Artelo Biosciences Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

Artelo Biosciences Inc dividends

ARTL dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ARTL stock

About the company Artelo Biosciences Inc

Market cap $B

0.004

Dividend yield

Shares outstanding

2.85569 B

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2015-10-13. The firm is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. The company is developing a dual cannabinoid agonist G protein-coupled receptor (GPCR) targeting synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer. Its second program, ART26.12 is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder. In addition, the Company is also developing ART12.11 (CBD cocrystal), its solid-state composition of cannabidiol (CBD).

ARTL profile

  • Ticker

    ARTL

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    13 October 2015

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    4

  • City

    Solana Beach

  • Address

    505 Lomas Santa Fe, Suite 160

  • Cusip

    04301G508